Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide and Talazoparib in Metastatic Hormone-Naïve Prostate Cancer
2023-509387-24-00Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) comparing Enzalutamide monotherapy with Enzalutamide + Talazoparib (2 arms). Primary endpoint: PSA complete response at 12 months. Started Aug 2024; status: completed.
02
Drugs
enzalutamidetalazoparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-509387-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509387-24-00.